Nefrologa, ‘scudo a declino cognitivo e obesità’. Il ruolo della neuroinfiammazione
Risultati per: Le cause della polmonite nei bambini
Questo è quello che abbiamo trovato per te
Biden contro vernice al piombo, 'minaccia la salute dei bambini'
L’Epa inasprisce gli standard per eliminarla in milioni case
Bronchiolite, un nuovo anticorpo preventivo protegge i bambini
Taglia del 90% i ricoveri, al Bambin Gesù 3 morti nel 2023/24
Il cambiamento climatico aumenta le allergie, più a rischio i bambini
Congresso allergologi, ‘accesso equo a cure su tutto territorio’
Cause of death by fibrosis stage in 959 patients with biopsy-proven NAFLD
We have read with interest the study from Simon et al, where the authors observed a higher mortality rate among patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) compared with reference controls without NAFLD.1 Importantly, mortality rates exhibited a significant increase as the severity of NAFLD worsened, that is, from simple steatosis, non-fibrotic nonalcoholic steatohepatitis (NASH), non-cirrhotic fibrosis (ie, F1–F3, with or without NASH) to cirrhosis. The leading causes of death were attributable to extrahepatic cancers and liver cirrhosis, while cardiovascular disease and hepatocellular carcinoma had a comparatively lesser impact. This extensive study of patients with NAFLD reveals higher mortality rates across different NAFLD stages but does not stratify causes of death within the respective pre-cirrhotic fibrosis stages (F0–F3). Owing to the long natural history of NAFLD, for example, patients with F0 and F1 may never experience liver-related events.2–4 For that…
I volontari Abio in piazza, per aiutare i bambini ricoverati
Sabato è la giornata #perAmore, si contribuisce cestino di pere
Un terzo dei casi mpox in Burundi tra i bambini in età scolare
Unicef, il numero crescente desta preoccupazioni
Occurrence of metabolic syndrome in midlife in relation to cardiovascular morbidity and all-cause mortality–lessons from a population-based matched cohort study with 27 years follow-up
Objectives
We examined how asymptomatic metabolic syndrome (MetS) in midlife affects cardiovascular (CV) morbidity and all-cause mortality later in life and studied difference in time to event and from the individual components related to MetS.
Design
Population-based matched cohort study including data from a screening programme for identification of CV risk factors.
Setting
Primary care, County of Västmanland, Sweden.
Participants
All inhabitants turning 40 or 50 years between 1990 and 1999 were invited to a health screening. Total 34 269 (60.1%) individuals completed the health examination. Participants that met a modified definition of MetS were individually matched to two controls without MetS with regard to age, sex and date of health examination.
Interventions
None.
Main outcome measures
CV events and all-cause mortality from the index examination to June 2022.
Results
All 5084 participants with MetS were matched to two controls. There were 1645 (32.4%) CV events in the MetS group and 2321 (22.8%) CV events for controls. 1317 (25.9%) MetS and 1904 (18.7%) control subjects died. The adjusted HRs (aHR) for CV event and death were significantly higher when MetS was present (aHR) 1.39*** (95% CI 1.28 to 1.50) and 1.27*** (95% CI 1.16 to 1.40) respectively. The factor analysis identified three dominating factors: blood pressure, cholesterol and blood glucose. Mean time for first CV event and death was 2.6 years and 1.5 years shorter respectively for participants within the highest quartile compared with participants with lower mean arterial blood pressure (MAP). The aHR for each 10 mm Hg increased MAP were 1.19*** (95% CI 1.15 to 1.23) for CV event and 1.16*** (95% CI 1.11 to 1.21) for death.
Conclusion
The risk of a CV event and premature death is significantly increased when MetS is present. Early detection of metabolic risk factors, especially, high blood pressure, opens a window of opportunity to introduce preventive treatment to reduce CV morbidity and all-cause mortality.
Does Absence of Pleocytosis in Cerebrospinal Fluid Exclude an Infectious Cause of Encephalitis?
Maybe not: In a large cohort of patients with infectious causes of encephalitis, almost one in five didn’t have CSF pleocytosis.
Multiple indicators of gut dysbiosis predict all-cause and cause-specific mortality in solid organ transplant recipients
Objective
Gut microbiome composition is associated with multiple diseases, but relatively little is known about its relationship with long-term outcome measures. While gut dysbiosis has been linked to mortality risk in the general population, the relationship with overall survival in specific diseases has not been extensively studied. In the current study, we present results from an in-depth analysis of the relationship between gut dysbiosis and all-cause and cause-specific mortality in the setting of solid organ transplant recipients (SOTR).
Design
We analysed 1337 metagenomes derived from faecal samples of 766 kidney, 334 liver, 170 lung and 67 heart transplant recipients part of the TransplantLines Biobank and Cohort—a prospective cohort study including extensive phenotype data with 6.5 years of follow-up. To analyze gut dysbiosis, we included an additional 8208 metagenomes from the general population of the same geographical area (northern Netherlands). Multivariable Cox regression and a machine learning algorithm were used to analyse the association between multiple indicators of gut dysbiosis, including individual species abundances, and all-cause and cause-specific mortality.
Results
We identified two patterns representing overall microbiome community variation that were associated with both all-cause and cause-specific mortality. The gut microbiome distance between each transplantation recipient to the average of the general population was associated with all-cause mortality and death from infection, malignancy and cardiovascular disease. A multivariable Cox regression on individual species abundances identified 23 bacterial species that were associated with all-cause mortality, and by applying a machine learning algorithm, we identified a balance (a type of log-ratio) consisting of 19 out of the 23 species that were associated with all-cause mortality.
Conclusion
Gut dysbiosis is consistently associated with mortality in SOTR. Our results support the observations that gut dysbiosis is associated with long-term survival. Since our data do not allow us to infer causality, more preclinical research is needed to understand mechanisms before we can determine whether gut microbiome-directed therapies may be designed to improve long-term outcomes.
A Rare Cause of liver injury in an adult
Malattia rara bambini, studio clinico Urbino migliora la terapia
Tecnologia dell’Università Carlo Bo esplora uso di globuli rossi
In MI with preserved LVEF, long-term β-blocker use vs. no use did not reduce all-cause death or MI at 3.5 y
Annals of Internal Medicine, Ahead of Print.
Association of Urinary Metals With Cardiovascular Disease Incidence and All-Cause Mortality in the Multi-Ethnic Study of Atherosclerosis (MESA)
Circulation, Ahead of Print. BACKGROUND:Exposure to metals has been associated with cardiovascular disease (CVD) end points and mortality, yet prospective evidence is limited beyond arsenic, cadmium, and lead. In this study, we assessed the prospective association of urinary metals with incident CVD and all-cause mortality in a racially diverse population of US adults from MESA (Multi-Ethnic Study of Atherosclerosis).METHODS:We included 6599 participants (mean [SD] age, 62.1 [10.2] years; 53% female) with urinary metals available at baseline (2000 to 2001) and followed through December 2019. We used Cox proportional hazards models to estimate the adjusted hazard ratio and 95% CI of CVD and all-cause mortality by baseline urinary levels of cadmium, tungsten, and uranium (nonessential metals), and cobalt, copper, and zinc (essential metals). The joint association of the 6 metals as mixture and the corresponding 10-year survival probability was calculated using Cox Elastic-Net.RESULTS:During follow-up, 1162 participants developed CVD, and 1844 participants died. In models adjusted by behavioral and clinical indicators, the HR (95% CI) for incident CVD and all-cause mortality comparing the highest with the lowest quartile were, respectively: 1.25 (1.03, 1.53) and 1.68 (1.43, 1.96) for cadmium; 1.20 (1.01, 1.42) and 1.16 (1.01, 1.33) for tungsten; 1.32 (1.08, 1.62) and 1.32 (1.12, 1.56) for uranium; 1.24 (1.03, 1.48) and 1.37 (1.19, 1.58) for cobalt; 1.42 (1.18, 1.70) and 1.50 (1.29, 1.74) for copper; and 1.21 (1.01, 1.45) and 1.38 (1.20, 1.59) for zinc. A positive linear dose-response was identified for cadmium and copper with both end points. The adjusted HRs (95% CI) for an interquartile range (IQR) increase in the mixture of these 6 urinary metals and the corresponding 10-year survival probability difference (95% CI) were 1.29 (1.11, 1.56) and –1.1% (–2.0, –0.05) for incident CVD and 1.66 (1.47, 1.91) and –2.0% (–2.6, –1.5) for all-cause mortality.CONCLUSIONS:This epidemiological study in US adults indicates that urinary metal levels are associated with increased CVD risk and mortality. These findings can inform the development of novel preventive strategies to improve cardiovascular health.